ACTUATE THERAPEUTICS, INC.
ACTU evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ACTU—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ACTU
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing elraglusib, a GSK-3β inhibitor, for advanced cancers; it has no approved products, no revenue, and a cash position of $4.4M as of June 30, 2026 [sec_mda].
Key risk: Cash runway insufficient
BioSniper Score
Based on 5 of 6 signals
Market Cap
$39.7M
Cash Runway
3.1 moLead Asset
elraglusib (Phase 1/Phase 2)Next Catalyst
Phase2_Start · Oct 1, 2026Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 2 clinical trials · 1 catalyst for ACTUATE THERAPEUTICS, INC..
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing elraglusib, a GSK-3β inhibitor, for advanced cancers; it has no approved products, no revenue, and a cash position of $4.4M as of June 30, 2026 [sec_mda].
- Lead candidate elraglusib (GSK-3β inhibitor) is being developed for refractory, metastatic melanoma and colorectal cancer [sec_mda · as of 2025-03-13].
- Cash and cash equivalents were $4.4M as of June 30, 2026, with working capital of $0.9M [sec_mda · as of 2026-08-14].
- Net loss was $4.9M for the quarter ended June 30, 2026 [latest reported financials].
- Accumulated deficit was approximately $125.9M as of September 30, 2024 [sec_mda · as of 2024-11-13].
- Company has no products approved for sale and has not generated any revenue from product sales since inception [sec_mda · as of 2025-03-13].
What works
- Elraglusib has advanced to a Phase 1/2 open-label, dose escalation study (Actuate-2401) for the oral tablet formulation, targeting multiple advanced refractory cancers [sec_mda · as of 2025-08-14].
- The company has developed several oral dosage forms of elraglusib, which management believes could expand the number of targetable cancer indications and offer more convenient dosing [sec_mda · as of 2025-08-14].
- Actuate has access to a Committed Equity Facility with 364,407 shares of common stock remaining capacity as of June 30, 2026, providing a potential source of future funding [sec_mda · as of 2026-08-14].
What to weigh
- Cash and cash equivalents of $4.4M as of June 30, 2026 are insufficient to fund operations for twelve months from the issuance date of the financial statements [sec_mda · as of 2026-08-14].
- The company has an accumulated deficit of approximately $125.9M (as of September 30, 2024) and expects losses to increase substantially as development and regulatory activities continue [sec_mda · as of 2024-11-13].
- No products are approved for sale, and the company has never generated revenue from product sales; profitability is uncertain and may never be achieved [sec_mda · as of 2025-03-13].
- There is no assurance that sufficient proceeds can be raised under the Committed Equity Facility or through other financings on acceptable terms [sec_mda · as of 2025-08-14].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“As of June 30, 2026, we had cash and cash equivalents of $4,425,841 and working capital of $942,745.”
SEC MD&A · August 14, 2026
Accumulated deficit as of September 30, 2024
“As of September 30, 2024, we had an accumulated deficit of approximately $125.9 million.”
SEC MD&A · November 13, 2024
No approved products or revenue from product sales
“We do not have any products approved for sale and have not generated any revenue from product sales since inception.”
SEC MD&A · March 13, 2025
Phase 1/2 study for elraglusib oral tablet
“A clinical candidate tablet, the Elraglusib Oral Tablet, has been selected for further development and we are planning a Phase 1 study (Actuate-2401) to identify the maximum tolerated dose ("MTD") and recommended Phase 2 dose ("RP2D") for Elraglusib Oral Tablet in patients with advanced, refractory adult cancers, subject to future funding.”
SEC MD&A · August 14, 2025
Catalyst timeline
- 2026-10-01 · Phase 2 Start — Phase 1/2 Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics — Initiation of the Phase 1/2 study for elraglusib oral tablet in advanced refractory cancers; enrollment and early safety data will be key to watch.
Risks & what to watch (4)›
Key risks
- Cash runway insufficient — Existing cash of $4.4M as of June 30, 2026 will not fund operations for twelve months [sec_mda · as of 2026-08-14].
- No revenue or approved products — Company has never generated product revenue and may never become profitable [sec_mda · as of 2025-03-13].
- Dependence on future financing — No assurance that Committed Equity Facility or other financings will provide sufficient funds [sec_mda · as of 2025-08-14].
- Clinical development risk — Elraglusib is in early-stage trials; failure could halt all operations [sec_mda · as of 2025-08-14].
What to watch
- Initiation and enrollment of the Phase 1/2 Actuate-2401 study for elraglusib oral tablet [sec_mda · as of 2025-08-14].
- Ability to raise additional capital through the Committed Equity Facility or other financings [sec_mda · as of 2026-08-14].
- Any clinical data readouts from ongoing or planned studies of elraglusib [sec_mda · as of 2025-08-14].
- Cash burn rate and whether the company can extend runway beyond current estimates [sec_mda · as of 2026-08-14].
Sources: SEC filings · SEC MD&A · Generated August 30, 2026 · How we verify sources →
Run ACTUATE THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ACTUATE THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
3.1 months
D/E 4.26 · 0% dilution
Lead: Phase 1/Phase 2
3 candidates
1 upcoming, next in ~32d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
60
Total value held
$34.4M
| Holder | Shares | Value |
|---|---|---|
| bios capital management, lp | 10,049,996 | $27.5M |
| vanguard capital management llc | 801,058 | $2.2M |
| blackrock, inc. | 427,153 | $1.2M |
| geode capital management, llc | 228,331 | $626K |
| connective capital management, llc | 113,266 | $310K |
| palogic value management, l.p. | 100,000 | $274K |
| northern trust corp | 97,851 | $268K |
| texas capital bank wealth management services inc | 94,592 | $259K |
| state street corp | 66,030 | $181K |
| vanguard fiduciary trust co | 62,592 | $172K |
Showing top 10 of 60 institutional holders of ACTUATE THERAPEUTICS, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 9.2%
- Days to cover
- 4.6
- Shares short
- 947,782
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ACTU short interestGovernance
Frequently asked questions
What is the AI investment thesis for ACTUATE THERAPEUTICS, INC.?
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing elraglusib, a GSK-3β inhibitor, for advanced cancers; it has no approved products, no revenue, and a cash position of $4.4M as of June 30, 2026 [sec_mda].
What is ACTUATE THERAPEUTICS, INC.'s lead drug candidate?
ACTUATE THERAPEUTICS, INC.'s most advanced tracked candidate is elraglusib (Phase 1/Phase 2) for Advanced Malignant Solid Tumor.
What is ACTUATE THERAPEUTICS, INC.'s next catalyst?
ACTUATE THERAPEUTICS, INC.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: Phase 1/2 Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, " — expected October 1, 2026.
Who is the CEO of ACTUATE THERAPEUTICS, INC.?
Mr. Daniel M. Schmitt is the chief executive officer of ACTUATE THERAPEUTICS, INC. (ACTU).
Where is ACTUATE THERAPEUTICS, INC. headquartered?
ACTUATE THERAPEUTICS, INC. (ACTU) is headquartered in Fort Worth, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.